CYP19A1 and breast cancer: Although aromatase immunohistochemistry is not used as an indicator of aromatase inhibition in patients with ER-positive breast cancer, it can be used to determine the local synthesis of estrogen in several cancer types (Miki et al. 2007, Miki et al. 2010, Grindstad et al. 2016).